• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23847 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Transoral robotic surgery: a review of clinical and cost-effectiveness
2024     NIHR Health Technology Assessment programme Transperineal biopsy devices in people with suspected prostate cancer - a systematic review and economic evaluation
2023     National Institute for Health and Care Excellence (NICE) Transperineal biopsy for diagnosing prostate cancer. NICE diagnostics guidance 54
2022     Norwegian Institute of Public Health (NIPH) Transperineal compared with transrectal biopsy on suspected prostate cancer: a health technology assessment
2025     National Institute for Health and Care Excellence (NICE) Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE interventional procedures guidance 798
2010     National Institute for Health and Care Excellence (NICE) Transperineal template biopsy and mapping of the prostate. NICE interventional procedures guidance 364
2002     HAYES, Inc. Transperineal ultrasound-guided brachytherapy for early-stage prostate cancer
2005     Technology Assessment Unit of the McGill University Health Centre (MUHC) Transplantation of allogeneic hematopoietic stem cells from unrelated donors in adult patients at the MUHC
2003     The Swedish Council on Health Technology Assessment (SBU) Transplantation of cultured skin (Apligraf(R)) in treating venous leg ulcers - early assessment briefs (Alert)
2001     The Swedish Council on Health Technology Assessment (SBU) Transplantation of stem cells from umbilical cord blood - early assessment briefs (Alert)
1994     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Transplantation with bone marrow not derived from HLA identical family donors for the treatment of adults and children with hemato-oncologic and congenital diseases - primary research
2002     Blue Cross Blue Shield Association (BCBS) Transplanting adult patients with hematopoietic stem cells from placental and umbilical cord blood
2012     NIHR Horizon Scanning Centre (NIHR HSC) Transportable haemodialysis machines for established renal failure
2007     New Zealand Health Technology Assessment (NZHTA) Transportation of emergency patients
2003     Institute for Clinical Effectiveness and Health Policy (IECS) Transpupillary thermotherapy
2002     NIHR Horizon Scanning Centre (NIHR HSC) Transpupillary thermotherapy for age-related macular degeneration - horizon scanning review
2004     National Institute for Health and Care Excellence (NICE) Transpupillary thermotherapy for age-related macular degeneration. NICE interventional procedures guidance 58
2002     HAYES, Inc. Transpupillary thermotherapy for choroidal tumors and macular degeneration
2011     Penn Medicine Center for Evidence-based Practice (CEP) Transradial access for cardiac catheterization
2013     HAYES, Inc. Transradial, transbrachial, and transulnar approaches for coronary angiography and intervention
1994     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Transurethral diathermy for benign prostatic hypertrophy: update -nonsystematic review
2003     National Institute for Health and Care Excellence (NICE) Transurethral electrovaporisation of the prostate. NICE interventional procedures guidance 14
2012     Medical Services Advisory Committee (MSAC) Transurethral injection of botulinum toxin into the ladder wall for urinary incontinence due to neurogenic detrusor overactivity
2019     National Institute for Health and Care Excellence (NICE) Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer. NICE interventional procedures guidance 656
2000     HAYES, Inc. Transurethral microwave thermotherapy
2007     HAYES, Inc. Transurethral microwave thermotherapy
2000     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia
2002     Medical Services Advisory Committee (MSAC) TransUrethral Needle Ablation (TUNA) for the treatment of benign prostatic hyperplasia
2005     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) Transurethral needle ablation (TUNA) in the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis
2001     ECRI Transurethral needle ablation [TUNA (R)] for benign prostatic hyperplasia
2001     HAYES, Inc. Transurethral needle ablation therapy
2007     HAYES, Inc. Transurethral radiofrequency micro-remodeling using the Renessa system (Novasys Medical Inc.) for female stress urinary incontinence
2010     HAYES, Inc. Transurethral Radiofrequency Micro-Remodeling Using the Renessa System (Novasys Medical Inc.) for Female Stress Urinary Incontinence
2018     National Institute for Health and Care Excellence (NICE) Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 625
2023     National Institute for Health and Care Excellence (NICE) Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 770
2021     National Institute for Health and Care Excellence (NICE) Transvaginal laser therapy for stress urinary incontinence. NICE interventional procedures guidance 696
2021     National Institute for Health and Care Excellence (NICE) Transvaginal laser therapy for urogenital atrophy. NICE interventional procedures guidance 697
2017     National Institute for Health and Care Excellence (NICE) Transvaginal mesh repair of anterior or posterior vaginal wall prolapse. NICE interventional procedures guidance 599
2011     HAYES, Inc. Transvaginal ultrasound for measurement of cervical length to predict preterm birth
2023     National Institute for Health and Care Excellence (NICE) Transvenous obliteration for gastric varices. NICE interventional procedures guidance 751
2016     NIHR Health Technology Assessment programme TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer
2004     HAYES, Inc. Trastuzumab (Herceptin (R)) for breast cancer
2007     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for advanced gastric cancer
2007     HAYES, Inc. Trastuzumab (Herceptin) for early breast cancer
2012     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for HER2 positive early breast cancer – two year regimen
2010     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer - neoadjuvant treatment
2001     The Swedish Council on Health Technology Assessment (SBU) Trastuzumab (Herceptin) for metastasized breast cancer - early assessment briefs (Alert)
2007     HAYES, Inc. Trastuzumab (Herceptin) for metastatic cancer
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Trastuzumab (Herceptin) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer
2006     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) in combination with aromatase inhibitors for stage IV - metastatic breast cancer: horizon scanning technology briefing
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Trastuzumab (Herceptin®)
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion
2003     ECRI Trastuzumab [Herceptin (R)] for the treatment of breast cancer
2005     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab as adjuvant therapy for early stage breast cancer - horizon scanning review
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer
2024     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy. NICE technology appraisal guidance 992
2024     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 976
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies
2023     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments. NICE technology appraisal guidance 862
2021     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies. NICE technology appraisal guidance 704
2023     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal). NICE technology appraisal guidance 879
2013     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab emtansine (Kadcyla) for patients with HER2 positive locally advanced or metastatic relapsed gastric cancers
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Trastuzumab emtansine (KadcylaTM) for previously treated patients with HER2-positive advanced/metastatic breast cancer
2020     National Institute for Health and Care Excellence (NICE) Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer. NICE technology appraisal guidance 632
2017     National Institute for Health and Care Excellence (NICE) Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane. NICE technology appraisal guidance 458
2012     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab emtansine in combination with pertuzumab for HER2-positive metastatic breast cancer – first line
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Trastuzumab for breast cancer treatment
2006     Quality Improvement Scotland (NHS QIS ) Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
2011     NIHR Health Technology Assessment programme Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2011     NIHR Health Technology Assessment programme Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2010     National Institute for Health and Care Excellence (NICE) Trastuzumab for the treatment of HER2-positive metastatic gastric cancer. NICE technology appraisal guidance 208
2009     NIHR Health Technology Assessment programme Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal
2020     Agency for Care Effectiveness (ACE) Trastuzumab for treating HER2-positive breast and gastric cancers
2011     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab SC (Herceptin SC) for breast cancer, early or metastatic, HER2 positive - monotherapy or combination therapy, including neo-adjuvant and adjuvant use
2011     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab-DM1 (Herceptin-DM1) for breast cancer, locally advanced or metastatic, HER2 positive - second or third line
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage
2011     Agency for Healthcare Research and Quality (AHRQ) Traumatic brain injury and depression.
2016     The Swedish Council on Health Technology Assessment (SBU) Traumatic shaking – The role of the triad in medical investigations of suspected traumatic shaking
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Travoprost (Travatan®)
2000     The Swedish Council on Health Technology Assessment (SBU) Treating asthma and COPD - a systematic review
1999     University of York Treating head lice and scabies
2001     The Swedish Council on Health Technology Assessment (SBU) Treating influenza by medication - zanamivir - early assessment briefs (ALERT)
2003     University of York Treating nocturnal enuresis in children
2003     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Treating osteoporosis with teriparatide: many unknowns?
2002     Norwegian Knowledge Centre for the Health Services (NOKC) Treating prostate cancer with brachytherapy
2011     Health Council of the Netherlands Gezondheidsraad (GR) Treating the effect of child abuse
2024     Swiss Federal Office of Public Health (FOPH) Treatment duration of trastuzumab in early HER2-positive breast cancer
2019     Agency for Healthcare Research and Quality (AHRQ) Treatment for acute pain: an evidence map
2017     Agency for Healthcare Research and Quality (AHRQ) Treatment for adults with schizophrenia
2018     Agency for Healthcare Research and Quality (AHRQ) Treatment for bipolar disorder in adults: a systematic review
2010     Institute of Health Economics (IHE) Treatment for convicted adult male sex offenders
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for depression after unsatisfactory response to SSRIs
2008     NIHR Health Technology Assessment programme Treatment for fibroids: Uterine Artery Embolisation (UAE) or hysterectomy (HOPEFUL) - Primary Research (e.g. trial)
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for glaucoma: comparative effectiveness
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for glaucoma: comparative effectiveness
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for hepatitis C virus infection in adults
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for restless legs syndrome
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment Foster Care Oregon for seriously delinquent adolescents
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies